Egle Therapeutics Raises 40 Million € Series a to Develop First-In-Class T-regulatory Cells Therapies Based On Treg-starvers
Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In-Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has completed a €40M ($46.4M) Series A financing. The Series A was co-led by LSP and Bpifrance through their InnoBio 2 fund. Fund+, Bioqube Ventures and Takeda Ventures, Inc. also participated in this round.
Egle Therapeutics was founded in early 2020 with a vision to become a game changer in the field of Tregs immunomodulation through the unique concept of Tregs starving and specifically targeting the most immunosuppressive ones. Spun out of Institut Curie, Egle’s scientific foundation leverages unprecedented, computational-based, IL-2 modified variants and newly tumor-associated Treg targets to build a furnished pipeline of First-In-Class immunocytokines against Tregs. The new capital will be used primarily to advance 2 leads assets into the clinic and further strengthen its internal drug pipeline.
“Closing a substantial Series A of €40M from a high-quality syndicate of renowned investors, as well as a partnership with a top big pharma like the one we have announced with Takeda in June 2020, all in less than 18 months, puts Egle on a trajectory to execute its vision of tackling regulatory T cells to restore immunity in patients suffering from cancer and autoimmune diseases” commented Luc Boblet, co-founder and CEO of Egle. “The funding will give us appropriate resources to push the first Treg starvers into the clinic and we feel very privileged to undertake such responsibility for the benefit of the whole patient community”.
The investor syndicate will join the Egle Therapeutics Board which will consist of Felice Verduyn-van Weegen (LSP), Vincent Brichard (LSP), Jean-Francois Morin (Bpifrance – InnoBio 2) and Sacha Mann (Takeda Ventures). Philippe Monteyne (Fund+), Jacques Mizrahi (Bioqube Ventures) and Elisa El Nouchi (Bpifrance InnoBio 2) will join as observers.
“Egle represents a strategic investment in a First-In-Class technology platform based on innovative research with novel T regulatory modulations and potential in the oncology and auto-immunity fields”, commented Vincent Brichard, Venture Partner at LSP. “We feel privileged to be part of such an exciting company, with world class science and look forward to build it out together with the team” adds Felice Verduyn-van Weegen, partner at LSP.
“InnoBio 2 strives to invest in breakthrough ideas and to promote First-In-Class drugs candidates. We are delighted to have co-led a financing round that will enable Egle Therapeutics to broadly invest in its platform technologies, development programs, people and ultimately, towards delivering a pioneering new generation of immunotherapies to patients in need,” said Jean-François Morin, Investment Director at Bpifrance.
About Egle Therapeutics
Established in early 2020, as a spin-out of Institut Curie by Luc Boblet, serial biotech entrepreneur and Dr Eliane Piaggio, PhD, renowned immunologist in the Treg / IL-2 field (INSERM Research Director, Head of the Translational Immunotherapy Team – TransImm – at Institut Curie), Egle Therapeutics develops First-In-Class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The key element of Egle’s core approach is the leveraging of its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. www.egle-tx.com
About LSP
LSP is one of the largest European investment firms providing financing for life sciences and health care companies. LSP’s management has raised over €2.7 billion ($3.2 billion) and supported the growth of 300 companies since it started to invest in 1988, including signature deals such as Argenx, Crucell and Neuravi. With offices in Amsterdam, Munich and Boston, LSP currently has the possibility to invest through five strategies, each having a distinctive investment scope and a dedicated team: LSP 6 invests in private early- to late-stage drug development and medical technology companies; LSP HEF 2 focuses on private late-stage medical technology companies; the LSP Dementia Fund invests in companies targeting neurodegenerative diseases; LSP Public targets public healthcare companies; and EBAC is the first healthcare SPAC to exclusively focus on European biotech. LSP is an active contributor to the global life sciences industry and the European life science eco-system by assuming for-profit and not-for-profit roles as initiators, founders and board members in various private and public bodies and organizations, for example being founder and board member of the Oncode Institute. lspvc.com.
About Bpifrance – InnoBio 2
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export).
InnoBio 2 is an investment fund dedicated to life sciences, managed by Bpifrance, which is also one of the LPs alongside Sanofi, Boehringer Ingelheim, Takeda, Ipsen, Servier, BMS and Pasteur Mutualité. InnoBio 2, aims to invest in companies developing innovative products and services, close to or in early clinical development, with the objective of bringing them until the clinical proof of concept. InnoBio 2 takes minority equity stake in companies and can lead or co-lead the investment rounds. www.bpifrance.com
About Takeda Ventures Inc.
Takeda Ventures, Inc. (TVI) is the corporate venture capital group of Takeda Pharmaceutical Company Limited and was founded in 2001 with the vision of generating disruptive technologies and therapeutic solutions for patients through venture-based partnerships. Their mission is to create strategic growth opportunities for Takeda by building, managing and investing in innovation-based companies. TVI partners with academic innovators, entrepreneurs and venture investors to create and nurture a portfolio of companies in an array of therapeutic areas, including oncology, gastroenterology, neuroscience and rare diseases. For more information visit www.takedaventures.com
About Fund+
Fund+ is an open-ended Fund for long term equity investment in innovative Life Sciences companies with a focus on Belgium and other European Biotech Hubs. We want to create sustainable shareholders value, contribute to the development of a leadership position in the Life Sciences sector and generate a tangible, beneficial societal impact. Fund+ has currently 16 innovative portfolio companies active in different therapeutic areas. https://fundplus.be
About Bioqube Ventures
Bioqube Ventures a specialist life sciences investment firm founded in 2016. The team consist out of investment professionals, sector experts and serial entrepreneurs that have a proven track record in successfully building and leading companies on their growth paths. In 2020, Bioqube Ventures launched the Bioqube Factory Fund I with a clear focus on the discovery and development of new therapeutic platforms and assets. With a diversified investment strategy, including a venture creation model and industry guidance through selected strategic partnerships, Bioqube Ventures will exclusively invest in the most promising innovative science in Europe. Bioqube Factory Fund I is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (“EFSI”) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing. www.bioqubeventures.com
About Institut Curie
Institut Curie, France’s leading cancer center, combines an internationally-renowned research center with a cutting-edge hospital group that treats all types of cancer, including the rarest. Founded in 1909 by Marie Curie, Institut Curie employs more than 3,700 researchers, physicians, and health professionals across three sites (Paris, Saint-Cloud, and Orsay), working on its three missions: treatment, research, and teaching. A private foundation with public utility status, Institut Curie is authorized to receive donations and legacies, and thanks to the support of its donors, is able to make discoveries more quickly, improving treatments and quality of life for patients. www.curie.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211022005007/en/
Contact information
Luc Boblet
Chief Executive Officer
Email: lboblet@egle-tx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARAMIS Global Ambassador, Dwyane Wade, Celebrates New Fragrance Launch During New York Fashion Week13.9.2025 20:13:00 EEST | Press release
Heritage men’s fragrance brand, ARAMIS, officially launched its new scent, Intuition, with global ambassador, Dwyane Wade, during New York Fashion Week. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250913048158/en/ ARAMIS Global Ambassador, Dwyane Wade, attends Brand’s NYFW Pop-Up at The High Line (Courtesy of BFA ) The celebration kicked off with an immersive pop-up on New York City’s iconic High Line, where guests explored the story behind the fragrance through scent, sound, and design. Dwyane Wade made a personal appearance at the interactive event, joined by his wife, actress Gabrielle Union. Later in the afternoon, Wade participated in an intimate conversation around personal grooming, fragrance, and modern masculinity at Bloomingdale's 59th Street. Moderated by Mike Muse, the conversation also featured Donato Smith, Wade's longtime barber, and friend. Bloomingdale’s top clients were given the opportunity to connect i
SUI Group Announces Completion of Existing $2 Million Stock Repurchase Program and Subsequent Authorization of New $50 Million Program12.9.2025 23:05:00 EEST | Press release
SUI Group Holdings Limited (“SUI Group,” “SUIG” or the “Company”) (NASDAQ: SUIG), the only publicly traded company with an official relationship with the Sui Foundation, today announced it has completed its previously authorized $2 million stock repurchase program. SUI Group is also announcing that its Board of Directors has now authorized a new stock repurchase program to acquire up to an additional $50 million of the Company’s common stock. Following the completion of its initial stock repurchase program, in which the Company repurchased approximately 318,743 shares of its common stock at an average price of $4.30 per share between September 10, 2025 and September 12, 2025, SUI Group’s new program provides the flexibility to support its Net Asset Value (“NAV”) per share by opportunistically purchasing its common stock. The Company believes that share repurchases at these levels are immediately accretive to existing stockholders and reflects its confidence in its underlying fundamenta
Allied Nations Gather to Discuss Future of Multilateral Defence Security Financing12.9.2025 18:35:00 EEST | Press release
The Defence, Security and Resilience Bank (DSRB) Development Group co-hosted an international conference in the City of London this week to discuss the creation of a new multilateral bank designed to bring capital market expertise to the frontlines of global security. The event at Mansion House, co-hosted by the Lord Mayor of London, included 72 attendees from 37 countries across the NATO alliance, the EU, and Indo-Pacific allied nations. Held on the eve of the Defence and Security Equipment International (DSEI event), the DSRB “Information Day” event also included a further 88 attendees from a wide range of institutions including the European Union, NATO, eight partner commercial banks, multiple development and central banks as well as representatives from global funds, ratings agencies, industry associations and think tanks. Notes to Editors: The DSR Bank Development Group is a non-profit working toward the establishment of the full bank alongside nation states and institutions. The
Illumination and Nintendo Announce the New Animated Film Based on the World of Super Mario Bros. Will Be Titled The Super Mario Galaxy Movie12.9.2025 16:33:00 EEST | Press release
Illumination (HQ: Santa Monica, CA, USA; Founder and CEO: Chris Meledandri) and Nintendo Co., Ltd. (HQ: Kyoto, Minami-ku, Japan; Representative Director and President: Shuntaro Furukawa, “Nintendo” hereafter) today announced that the title of the new animated film based on the world of Super Mario Bros., will be The Super Mario Galaxy Movie. The film will be released worldwide by Universal Pictures beginning April 3, 2026. In addition, the two companies announced that the returning voice actors for the characters will be: Mario (Chris Pratt), Princess Peach (Anya Taylor-Joy), Luigi (Charlie Day), Bowser (Jack Black), Toad (Keegan-Michael Key), and Kamek (Kevin Michael Richardson). The additional characters and voice cast for The Super Mario Galaxy Movie will be announced at a later date. The Super Mario Galaxy Movie will be released on April 3, 2026 in the US and many additional markets globally, and will be released on April 24, 2026 in Japan, with select territories releasing through
TON Strategy Company Announces Initial Share Repurchases Under $250 Million Program, Buying Below Treasury Asset Value Per Share, and Start of Staking12.9.2025 15:30:00 EEST | Press release
TON Strategy Company (Nasdaq: TONX) (the “Company”), a digital asset treasury company committed to holding Toncoin ($TON), today announced that it has repurchased over 250,000 shares of its common stock under its previously announced $250 million share repurchase program. Further, the Company has started staking operations, as planned, to generate on-chain income by utilizing its treasury holdings. The Company repurchased shares at an average of $8.32 per share; by comparison, the Company’s TAV per share was $12.181 as of September 11, 2025. This week’s share repurchases and the start of staking underscore TON Strategy Company’s financial strength, commitment to shareholder value, and long-term confidence in The Open Network (TON) ecosystem. They coincide with recent milestones in the broader TON network – including the availability of $TON on Gemini, Robinhood, and Zengo – which the Company believes represent steps toward broader market access for the token as the native asset of TON,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom